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Abstract
Osteoclast activation is a critical cellular process for pathological bone resorption, such as
erosions in rheumatoid arthritis (RA) or generalized bone loss.  Among many factors triggering
excessive osteoclast activity, cytokines such as IL-1 or tumour necrosis factor (TNF)-a play a
central role. New members of the TNF receptor ligand family (namely receptor activator of
nuclear factor-kB [RANK] and RANK ligand [RANKL]) have been discovered whose cross-
interaction is mandatory for the differentiation of osteoclasts from hemopoietic precursors, in
both physiological and pathological situations. Osteoprotegerin, a decoy receptor which
blocks this interaction, decreases osteoclast activity and could have a fascinating therapeutic
potential in conditions associated with upregulated bone resorption.
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nuclear factor-kB ligand; TNF = tumour necrosis factor.
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Introduction
Bone remodelling is a continuous physiological process
that occurs in adult skeleton in which bone resorption is
followed by new bone formation, maintaining mechanical
strength and structure. Bone cells that are responsible for
this coupled process include bone-resorbing cells (osteo-
clasts, which are derived from haematopoietic cells of the
monocyte/macrophage lineage) and bone-forming cells
(osteoblasts, which are of mesenchymal origin). The bone
resorption process is involved in many clinical situations
that are relevant to the work of rheumatologists, such as
focal bone destruction or erosion in RA and other inflam-
matory arthritides, and the diffuse bone loss that is
encountered in osteoporosis.
Osteoclast differentiation: basic mechanisms
and new insights
Osteoclast progenitor cells are recruited from haemato-
poietic compartments, and then proliferate and differenti-
ate toward mature osteoclasts. During this multistep
differentiation process postmitotic osteoclast precursors
progressively express osteoclast-associated markers, suchArthritis Research    Vol 2 No 6 Roux and Orcel
as calcitonin receptor and tartrate-resistant acid phos-
phatase, as they lose some of their macrophage character-
istics. Then, mononuclear preosteoclasts fuse together to
form multinucleated giant cells. Terminal osteoclast differ-
entiation eventually leads to active bone-resorbing cells [1].
Role of osteoblast/stromal cells in osteoclast
differentiation
Biological models of in vitro osteoclast differentiation have
been developed that have facilitated detailed study of
many of the factors involved in the regulation of this
process. The most commonly studied models are cultures
of mouse bone marrow or cocultures of haematopoietic
cells with bone-derived stromal cells, which give rise to
large numbers of bone-resorbing osteoclasts [2]. Studies
based on these models have found that mesenchymally
derived stromal cells play a critical role in supporting and
stimulating osteoclast differentiation, a process that prob-
ably necessitates cell–cell contact between osteoclast
precursors and stromal cells [3,4]. In some human models,
however, a cellular interaction between osteoclast precur-
sors and stromal cells is not always required [5–7].
Local and hormonal factors that are involved in osteoclast
differentiation
Bone resorption is closely controlled in vivo by cellular
and hormonal factors, which affect not only osteoclast
activity, but also osteoclast formation. Parathyroid
hormone (PTH) and 1,25-dihydroxyvitamin D3 [1,25(OH)2D3]
increase bone resorption, primarily via an indirect mecha-
nism that is mediated by osteoblasts [2]. Oestrogens have
a negative impact on osteoclast differentiation, and oestro-
gen deficiency leads to increased osteoclast differentia-
tion and activation [8]. The cytokines IL-1, IL-6 and TNF-a
are known to increase bone resorption by stimulating both
osteoclast activity and differentiation. This effect involves,
at least in part, prostaglandin production [9,10]. The major
role of macrophage colony-stimulating factor (M-CSF) has
been pointed out in M-CSF-deficient (op/op) mice, which
develop an osteopetrosis that is characterized by the
absence of osteoclasts [11]. Studies using murine cocul-
tures [12] have shown that M-CSF acts both on prolifera-
tion and on differentiation of precursor cells. Local
injections of M-CSF in rat metaphyseal bone also increase
in situ osteoclast differentiation and bone resorption [13].
Other cytokines stimulate bone resorption at least partly
by increasing osteoclast differentiation, such as leukaemia
inhibiting factor and IL-11 [14,15]. Conversely, some
cytokines such as IL-4 or IFN-g have been shown to inhibit
osteoclast differentiation in vitro [16]. The role of trans-
forming growth factor-b is more complex; it decreases
osteoclast precursor proliferation and bone resorption
activity [17,18], but it also increases the expression of
two osteoclastic markers – vitronectin receptor and calci-
tonin receptor [19,20]. Most of the cytokines that regu-
late osteoclast differentiation are produced in the bone
microenvironment, mainly by osteoblast/stromal cells,
further emphasizing the key role of these cells in osteo-
clast differentiation.
A new interactive system in osteoclast bone
resorption
The recent discovery of new members of the TNF receptor
ligand family has pointed out the crucial role of RANK and
RANKL in osteoclast differentiation and activation [21•,
22•] (Fig. 1).
RANKL, also called osteoclast differentiation factor (ODF),
TNF-related induced cytokine (TRANCE), or
osteoprotegerin ligand (OPGL)
Because osteoblast–stromal cell interactions with osteo-
clast precursors are required for subsequent osteoclast
differentiation, an ODF expressed by these cells and rec-
ognized by osteoclast precursors was suspected. Such a
factor was identified as RANKL [23••,24••]. RANKL is a
membrane-bound TNF-related factor that is expressed by
osteoblast/stromal cells. That the presence of RANKL is
vital in osteoclast differentiation is now well established,
and its soluble recombinant form has been tested in a
number of in vitro and in vivo studies. In in vitro murine or
human osteoclast differentiation models, soluble RANKL
enables osteoclast precursors to differentiate in the pres-
ence of M-CSF, even in the absence of osteoblast/stromal
cells [25••,26]. Bone resorption activity is increased, as
well as the osteoclast survival [23••,26]. Mice that are
defective for RANKL develop a form of osteopetrosis.
They are characterized by the absence of osteoclasts,
although osteoclast progenitors are present and are able
to differentiate into bone-resorbing osteoclasts in the
presence of normal osteoblast/stromal cells [27••].
In addition, the soluble form of RANKL has been shown to
be produced by human fibroblasts transfected with an
expression vector for RANKL and by in vitro activated
murine T cells [23••,28]. However, it is not clear whether
this soluble form plays a role in vivo in normal bone homeo-
stasis or in pathological processes that are characterized
by increased bone resorption.
RANK
Osteoclast precursors express RANK, a membrane-bound
TNF receptor that recognizes RANKL through a direct
cell–cell interaction with osteoblast/stromal cells [29••].
Recent studies [29••,30] demonstrated that this receptor is
essential for the transduction of signals that lead to osteo-
clast differentiation. An overexpression of soluble RANK
results in osteopetrosis, with a decreased number of osteo-
clasts [30]. Conversely, mice that are deficient for RANK
develop a severe osteopetrosis that is characterized by the
absence of osteoclasts. In addition, osteoclast precursors
in these mice are unable to differentiate to osteoclasts in
vitro, in the presence of RANKL and M-CSF [31].http://arthritis-research.com/content/2/6/451
Osteoprotegerin
Osteoprotegerin is a member of the TNF receptor family
that lacks a transmembrane domain and represents a
secreted receptor. Osteoprotegerin recognizes RANKL,
and this decoy receptor blocks the interaction between
RANK and RANKL, leading to an inhibition of osteoclast
differentiation and activation [32••,33••]. Overexpression of
osteoprotegerin in transgenic mice results in a form of
osteopetrosis that is characterized by a defect in osteo-
clast differentiation [32••]. By contrast, osteoprotegerin-
deficient mice develop severe osteoporosis because of
increased osteoclast differentiation and function [34••]. In
vitro studies have demonstrated the strong inhibitory action
of osteoprotegerin on osteoclast differentiation, as well as
on the bone-resorbing activity of osteoclasts [32••,33••].
Role of RANK/RANKL and osteoprotegerin in
osteoclast differentiation
RANKL/osteoprotegerin balance, signal transduction and
osteoclast differentiation
Recent data suggest that M-CSF and RANKL are two
major factors involved in osteoclast differentiation. M-CSF
is required for both proliferation and differentiation, and
RANKL (which is not a growth factor) is required for differ-
entiation into mature osteoclasts and for osteoclast activ-
ity [26]. In bone tissue, osteoprotegerin and RANKL are
expressed by osteoblast/stromal cells, and the ratio of
these products may modulate the ability of these cells to
stimulate osteoclast differentiation/activity, as well as the
rate of bone resorption [21•].
In addition, it has been shown [26] that the interaction
between RANKL and RANK results in a transduction
signal in preosteoclasts and in mature osteoclasts that
may activate nuclear factor-k (NF-kB). The role of NF-kB
in the osteoclast differentiation has been previously
demonstrated in mice with a double knockout for the p50
and p52 NF-kB subunits, in which a defect of osteoclast
differentiation leads to an osteopetrosis [35,36]. Other
intracellular events are activated by transduction signals,
such as c-jun terminal kinase, and TNF receptor-associ-
ated factors, which regulate activation of NF-kB and/or
c-jun terminal kinase [21•].
RANK/RANKL, immune cells and osteoclast differentiation
RANK and RANKL have been shown to be expressed in
dendritic cells and T lymphocytes, respectively, in which
they appear to be important regulators of the interactions
between these cells [37,38]. These data suggest that,
apart from osteoclast differentiation and activation, RANK
and RANKL are involved in the immune system as sug-
gested by the mice knockout models. RANKL-deficient
mice lack lymph nodes and exhibit defects in differentia-
tion of T and B lymphocytes [27••], and RANK-deficient
mice exhibit a marked deficiency in B cells in the spleen
and lack lymph nodes [31].
Regulation of RANKL and osteoprotegerin expression
Recent studies have demonstrated that osteotropic
factors and hormones such as PTH, 1,25(OH)2D3, IL-11,
IL-1b, TNF-a or prostaglandin E2 upregulate RANKL
expression in osteoblast/stromal cells (Fig. 1). In addition,
osteoprotegerin expression is downregulated by
prostaglandin E2, and is upregulated by oestrogens [21•].
RANK expression has not yet been extensively studied.
An integrated view and clinical implications
An emerging concept is that cytokines and hormonal
factors that are involved in bone resorption may act by a
common final pathway involving RANKL and RANK [21•].
In accordance with this concept, a recent in vivo study
[39••] has shown that a recombinant chimaeric Fc fusion
form of osteoprotegerin inhibited hypercalcaemia and bone
resorption induced by IL-1b, TNF-a, PTH and 1,25(OH)2D3
in mice. This convergence theory is probably not exclusive
because recent studies [40,41] have suggested that the
effects of TNF-a or IL-6 may involve different effectors.
Therapeutic perspectives
The concept presented above will probably lead to new
therapeutic approaches in several diseases that are char-
acterized by excessive bone resorption. Thus, osteoprote-
Figure 1
New members of the TNF receptor ligand family: role of RANKL (ODF,
TRANCE, OPGL) and its receptor RANK in osteoclast differentiation.
RANKL, a membrane-bound TNF-related factor, is expressed by
osteoblast/stromal cells and is upregulated by osteotropic factors such
as 1,25(OH)2D3, PTH, IL-6 or IL-11. Osteoclast (OC) precursors
express RANK, a membrane-bound TNF receptor, that recognizes
RANKL through cell–cell interaction with osteoblast/stromal cells. This
interaction enables osteoclast precursors to differentiate in the
presence of M-CSF. Osteoprotegerin (OPG) is a member of the TNF
receptor family that lacks a transmembrane domain and represents a
secreted TNF receptor. OPG recognizes RANKL, and this decoy
receptor blocks the interaction between RANK and RANKL, leading to
inhibition of osteoclast differentiation and activation.gerin (a specific inhibitor of RANKL) or an analogue may
be used to block the excess of bone resorption in patho-
logical conditions such as hyper-resorption of malignancy,
in which this pathway seems to be primarily involved
[42••], or in osteoporosis, in which oestrogen deficiency
could lead to decreased production of osteoprotegerin
and subsequent increased bone resorption.
Bone erosions in rheumatoid arthritis
Rheumatoid arthritis is another interesting clinical model
for the study of the role of RANK/RANKL in bone ero-
sions, and as a therapeutic target for osteoprotegerin.
Rheumatoid arthritis is characterized by progressive bone
and cartilage destruction as a result of chronic synovitis.
Numerous studies have pointed out the role of cytokines
such as TNF-a or IL-1 in the joint destruction [43]. Recent
studies suggest that RANKL mRNA is highly expressed in
synovial tissues from patients with RA, but not in normal
synovial tissues. This expression is detected in synovial
fibroblasts, as well as in activated T cells derived from RA
synovial tissues, suggesting that these cells may con-
tribute to osteoclast formation at the specific sites of bone
destruction in RA [44•,45•]. In addition, in rat adjuvant-
induced arthritis, RANKL is expressed on the surface of
activated T cells isolated from affected rats, and may be
secreted in T cell cultures. Activated T cells could there-
fore directly induce osteoclastogenesis through mem-
brane-bound and soluble RANKL [28]. These data
suggest that RANKL may have a major pathophysiological
importance in the bone and joint destruction observed in
inflammatory arthritides such as RA. Activated T cells,
which play a central role in the pathogenesis of RA, may
(in addition to stromal cells) contribute to the osteoclast-
mediated bone resorption via RANKL expression [46••].
Conclusion
Osteoclasts are multinucleated cells that are formed by
fusion of osteoclast precursors from haematopoietic
origin. These cells are responsible for bone resorption
and osteoclast differentiation and represent an evident
point of control of bone resorption. Bone resorption is
closely regulated in vivo by many cellular and hormonal
factors, which affect not only osteoclast activity, but also
osteoclast formation. The recent discovery of new
members of the TNF receptor ligand family (ODF, TNF-
related induced cytokine, osteoprotegerin ligand) have
emphasized the crucial role of RANKL, which is
expressed by osteoblast/stromal cells, and its receptor
RANK, which is expressed by osteoclast cells, in osteo-
clast differentiation and activation. This system is com-
pleted by osteoprotegerin, which is a secreted TNF
receptor. Osteoprotegerin recognizes RANKL, and this
decoy receptor blocks the interaction between RANK
and RANKL. A number of osteotropic factors and hor-
mones may modulate bone resorption via this common
final pathway, which may represent a potential therapeu-
tic target in pathologic processes that are characterized
by excessive bone resorption.
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